Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity

Journal of Medicinal Chemistry

Volumn 59, Issue 11, 2016, Pages 5377-5390

  Bommineni, Gopal R ^a   Kapilashrami, Kanishk ^a,c   Cummings, Jason E ^b   Lu, Yang ^a   Knudson, Susan E ^b   Gu, Chendi ^a   Walker, Stephen G ^a   Slayden, Richard A ^b   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2,5 DIHYDRO 2 METHYL 2 (2 METHYLBUTA 1,3 DIENYL) 5 OXOTHIOPHEN 3 YLOXY] N (2 AZIDOETHYL)ACETAMIDE; 3 (2 CARBOXYBENZOYL) 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 (2,2,2 TRIFLUOROACETYL) 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 (3 AZIDOHEXANOYL) 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 (3 AZIDOPROPYL) 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 (4 AZIDOBUTYL) 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 (4 CHLOROPHENETHYL) 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 (4 METHYLPHENETHYL) 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 (4 PHENYL PHENYLHEXANOYL) 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 ACETYL 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 BUTYRYL 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 ETHYL 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE; 3 [4 (4 BROMOPHENYL)BUTYL] 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 [4 (4 CHLOROPHENYL)BUTYL] 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 [4 (4 FLUOROPHENYL)BUTYL] 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 3 [4 (4 PHENYLPHENYL)BUTYL] 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL) 3 PALMITOYLTHIOPHEN 2(5H) ONE; 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL) 3 PROPYLTHIOPHEN 2(5H) ONE; 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL)THIOPHEN 2(5H) ONE; 4 [(4 FLUOROPHENYLSULFONYL)AMINO] N [[1 [4 [2,5 DIHYDRO 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL) 2 OXOTHIOPHEN 3 YL]BUTYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL]BENZAMIDE; GENTAMICIN; METHYL 2,5 DIHYDRO 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL) 2 OXOTHIOPHENE 3 CARBOXYLATE; N [[1 [2 [2 [2,5 DIHYDRO 2 METHYL 2 (2 METHYLBUTA 1,3 DIENYL) 5 OXOTHIOPHEN 3 YLOXY]ACETAMIDO]ETHYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL] 2,4 DIHYDROXY 3,3 DIMETHYLBUTANAMIDE; N [[1 [2 [2 [2,5 DIHYDRO 2 METHYL 2 (2 METHYLBUTA 1,3 DIENYL) 5 OXOTHIOPHEN 3 YLOXY]ACETAMIDO]ETHYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL] 4 [(4 FLUOROPHENYLSULFONYL)AMINO]BENZAMIDE; N [[1 [4 [2,5 DIHYDRO 4 HYDROXY 5 METHYL 5 (2 METHYLBUTA 1,3 DIENYL) 2 OXOTHIOPHEN 3 YL]BUTYL] 1H 1,2,3 TRIAZOL 4 YL]METHYL] 2,4 DIHYDROXY 3,3 DIMETHYLBUTANAMIDE; TERT BUTYL 2 [2 [2,5 DIHYDRO 2 METHYL 2 (2 METHYLBUTA 1,3 DIENYL) 5 OXOTHIOPHEN 3 YLOXY]ACETAMIDO]ETHYLCARBAMATE; THIOLACTOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; ENZYME INHIBITOR; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME INHIBITION; FRANCISELLA TULARENSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; CONFORMATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; YERSINIA PESTIS;

3-OXOACYL-(ACYL-CARRIER-PROTEIN) SYNTHASE; ANIMALS; ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; CELL LINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FRANCISELLA TULARENSIS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; YERSINIA PESTIS;

EID: 84974577396     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00236     Document Type: Article

References (56)

1. Wright, G. D. The antibiotic resistome: the nexus of chemical and genetic diversity Nat. Rev. Microbiol. 2007, 5, 175-186 10.1038/nrmicro1614
2. McGowan, J. E., Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum Am. J. Infect. Control 2006, 34, S29-37 discussion S64-S73. 10.1016/j.ajic.2006.05.226
3. Giamarellos-Bourboulis, E. J.; Antonopoulou, A.; Raftogiannis, M.; Koutoukas, P.; Tsaganos, T.; Tziortzioti, V.; Panagou, C.; Adamis, T.; Giamarellou, H. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa BMC Infect. Dis. 2006, 6, 31 10.1186/1471-2334-6-31
4. CDC Staphylococcus aureus resistant to vancomycin - United States, 2002 MMWR Morb. Mortal. Wkly. Rep. 2002, 51, 565-567
5. Magnuson, K.; Jackowski, S.; Rock, C. O.; Cronan, J. E., Jr. Regulation of fatty acid biosynthesis in Escherichia coli Microbiol. Rev. 1993, 57, 522-542
6. Rock, C. O.; Cronan, J. E. Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis Biochim. Biophys. Acta, Lipids Lipid Metab. 1996, 1302, 1-16 10.1016/0005-2760(96)00056-2
7. Campbell, J. W.; Cronan, J. E., Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery Annu. Rev. Microbiol. 2001, 55, 305-332 10.1146/annurev.micro.55.1.305
8. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K. S.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs, W. R., Jr. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis Science 1994, 263, 227-230 10.1126/science.8284673
9. Dessen, A.; Quemard, A.; Blanchard, J. S.; Jacobs, W. R., Jr.; Sacchettini, J. C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis Science 1995, 267, 1638-1641 10.1126/science.7886450
10. Quemard, A.; Sacchettini, J. C.; Dessen, A.; Vilcheze, C.; Bittman, R.; Jacobs, W. R., Jr.; Blanchard, J. S. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis Biochemistry 1995, 34, 8235-8241 10.1021/bi00026a004
11. Rawat, R.; Whitty, A.; Tonge, P. J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 13881-13886 10.1073/pnas.2235848100
12. Escaich, S.; Prouvensier, L.; Saccomani, M.; Durant, L.; Oxoby, M.; Gerusz, V.; Moreau, F.; Vongsouthi, V.; Maher, K.; Morrissey, I.; Soulama-Mouze, C. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound Antimicrob. Agents Chemother. 2011, 55, 4692-4697 10.1128/AAC.01248-10
13. Flamm, R. K.; Rhomberg, P. R.; Kaplan, N.; Jones, R. N.; Farrell, D. J. Activity of Debio1452, a Fabi inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains Antimicrob. Agents Chemother. 2015, 59, 2583-2587 10.1128/AAC.05119-14
14. Park, H. S.; Yoon, Y. M.; Jung, S. J.; Yun, I. N.; Kim, C. M.; Kim, J. M.; Kwak, J. H. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor Int. J. Antimicrob. Agents 2007, 30, 446-451 10.1016/j.ijantimicag.2007.07.006
15. Heath, R. J.; Rock, C. O. The Claisen condensation in biology Nat. Prod. Rep. 2002, 19, 581-596 10.1039/b110221b
16. Davies, C.; Heath, R. J.; White, S. W.; Rock, C. O. The 1.8 A crystal structure and active-site architecture of β-ketoacyl-acyl carrier protein synthase III (FabH) from Escherichia coli Structure 2000, 8, 185-195 10.1016/S0969-2126(00)00094-0
17. Jackowski, S.; Rock, C. O. Acetoacetyl-acyl carrier protein synthase, a potential regulator of fatty acid biosynthesis in bacteria J. Biol. Chem. 1987, 262, 7927-7931
18. Borgaro, J. G.; Chang, A.; Machutta, C. A.; Zhang, X.; Tonge, P. J. Substrate recognition by β-ketoacyl-ACP synthases Biochemistry 2011, 50, 10678-10686 10.1021/bi201199x
19. Yuan, Y. Q.; Sachdeva, M.; Leeds, J. A.; Meredith, T. C. Fatty acid biosynthesis in Pseudomonas aeruginosa is initiated by the FabY class of β-ketoacyl acyl carrier protein synthases J. Bacteriol. 2012, 194, 5171-5184 10.1128/JB.00792-12
20. Wright, H. T.; Reynolds, K. A. Antibacterial targets in fatty acid biosynthesis Curr. Opin. Microbiol. 2007, 10, 447-453 10.1016/j.mib.2007.07.001
21. Young, K.; Jayasuriya, H.; Ondeyka, J. G.; Herath, K.; Zhang, C.; Kodali, S.; Galgoci, A.; Painter, R.; Brown-Driver, V.; Yamamoto, R.; Silver, L. L.; Zheng, Y.; Ventura, J. I.; Sigmund, J.; Ha, S.; Basilio, A.; Vicente, F.; Tormo, J. R.; Pelaez, F.; Youngman, P.; Cully, D.; Barrett, J. F.; Schmatz, D.; Singh, S. B.; Wang, J. Discovery of FabH/FabF inhibitors from natural products Antimicrob. Agents Chemother. 2006, 50, 519-526 10.1128/AAC.50.2.519-526.2006
22. Ondeyka, J. G.; Zink, D. L.; Young, K.; Painter, R.; Kodali, S.; Galgoci, A.; Collado, J.; Tormo, J. R.; Basilio, A.; Vicente, F.; Wang, J.; Singh, S. B. Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy J. Nat. Prod. 2006, 69, 377-380 10.1021/np050416w
23. Wang, J.; Soisson, S. M.; Young, K.; Shoop, W.; Kodali, S.; Galgoci, A.; Painter, R.; Parthasarathy, G.; Tang, Y. S.; Cummings, R.; Ha, S.; Dorso, K.; Motyl, M.; Jayasuriya, H.; Ondeyka, J.; Herath, K.; Zhang, C.; Hernandez, L.; Allocco, J.; Basilio, A.; Tormo, J. R.; Genilloud, O.; Vicente, F.; Pelaez, F.; Colwell, L.; Lee, S. H.; Michael, B.; Felcetto, T.; Gill, C.; Silver, L. L.; Hermes, J. D.; Bartizal, K.; Barrett, J.; Schmatz, D.; Becker, J. W.; Cully, D.; Singh, S. B. Platensimycin is a selective FabF inhibitor with potent antibiotic properties Nature 2006, 441, 358-361 10.1038/nature04784
24. Wang, J.; Kodali, S.; Lee, S. H.; Galgoci, A.; Painter, R.; Dorso, K.; Racine, F.; Motyl, M.; Hernandez, L.; Tinney, E.; Colletti, S. L.; Herath, K.; Cummings, R.; Salazar, O.; Gonzalez, I.; Basilio, A.; Vicente, F.; Genilloud, O.; Pelaez, F.; Jayasuriya, H.; Young, K.; Cully, D. F.; Singh, S. B. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 7612-7916 10.1073/pnas.0700746104
25. Noto, T.; Miyakawa, S.; Oishi, H.; Endo, H.; Okazaki, H. Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity J. Antibiot. 1982, 35, 401-410 10.7164/antibiotics.35.401
26. Oishi, H.; Noto, T.; Sasaki, H.; Suzuki, K.; Hayashi, T.; Okazaki, H.; Ando, K.; Sawada, M. Thiolactomycin, a new antibiotic. I. Taxonomy of the producing organism, fermentation and biological properties J. Antibiot. 1982, 35, 391-395 10.7164/antibiotics.35.391
27. Miyakawa, S.; Suzuki, K.; Noto, T.; Harada, Y.; Okazaki, H. Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice J. Antibiot. 1982, 35, 411-419 10.7164/antibiotics.35.411
28. Hamada, S.; Fujiwara, T.; Shimauchi, H.; Ogawa, T.; Nishihara, T.; Koga, T.; Nehashi, T.; Matsuno, T. Antimicrobial activities of thiolactomycin against Gram-negative anaerobes associated with periodontal disease Oral Microbiol. Immunol. 1990, 5, 340-345 10.1111/j.1399-302X.1990.tb00438.x
29. Slayden, R. A.; Lee, R. E.; Armour, J. W.; Cooper, A. M.; Orme, I. M.; Brennan, P. J.; Besra, G. S. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis Antimicrob. Agents Chemother. 1996, 40, 2813-2819
30. Price, A. C.; Choi, K. H.; Heath, R. J.; Li, Z.; White, S. W.; Rock, C. O. Inhibition of β-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism J. Biol. Chem. 2001, 276, 6551-6559 10.1074/jbc.M007101200
31. Kim, P.; Barry, C. E.; Dowd, C. S. Novel route to 5-position vinyl derivatives of thiolactomycin: Olefination vs. deformylation Tetrahedron Lett. 2006, 47, 3447-3451 10.1016/j.tetlet.2006.03.058
32. Machutta, C. A.; Bommineni, G. R.; Luckner, S. R.; Kapilashrami, K.; Ruzsicska, B.; Simmerling, C.; Kisker, C.; Tonge, P. J. Slow onset inhibition of bacterial β-ketoacyl-acyl carrier protein synthases by thiolactomycin J. Biol. Chem. 2010, 285, 6161-6169 10.1074/jbc.M109.077909
33. Kapilashrami, K.; Bommineni, G. R.; Machutta, C. A.; Kim, P.; Lai, C. T.; Simmerling, C.; Picart, F.; Tonge, P. J. Thiolactomycin-based β-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy J. Biol. Chem. 2013, 288, 6045-6052 10.1074/jbc.M112.414516
34. Senior, S. J.; Illarionov, P. A.; Gurcha, S. S.; Campbell, I. B.; Schaeffer, M. L.; Minnikin, D. E.; Besra, G. S. Biphenyl-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme Bioorg. Med. Chem. Lett. 2003, 13, 3685-3688 10.1016/j.bmcl.2003.08.015
35. Senior, S. J.; Illarionov, P. A.; Gurcha, S. S.; Campbell, I. B.; Schaeffer, M. L.; Minnikin, D. E.; Besra, G. S. Acetylene-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme Bioorg. Med. Chem. Lett. 2004, 14, 373-376 10.1016/j.bmcl.2003.10.061
36. Bhowruth, V.; Brown, A. K.; Senior, S. J.; Snaith, J. S.; Besra, G. S. Synthesis and biological evaluation of a C5-biphenyl thiolactomycin library Bioorg. Med. Chem. Lett. 2007, 17, 5643-5646 10.1016/j.bmcl.2007.07.082
37. Jones, S. M.; Urch, J. E.; Kaiser, M.; Brun, R.; Harwood, J. L.; Berry, C.; Gilbert, I. H. Analogues of thiolactomycin as potential antimalarial agents J. Med. Chem. 2005, 48, 5932-5941 10.1021/jm049067d
38. Jones, A. L.; Herbert, D.; Rutter, A. J.; Dancer, J. E.; Harwood, J. L. Novel inhibitors of the condensing enzymes of the type II fatty acid synthase of pea (Pisum sativum) Biochem. J. 2000, 347, 205-209 10.1042/bj3470205
39. Jones, S. M.; Urch, J. E.; Brun, R.; Harwood, J. L.; Berry, C.; Gilbert, I. H. Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents Bioorg. Med. Chem. 2004, 12, 683-692 10.1016/j.bmc.2003.11.023
40. McFadden, J. M.; Medghalchi, S. M.; Thupari, J. N.; Pinn, M. L.; Vadlamudi, A.; Miller, K. I.; Kuhajda, F. P.; Townsend, C. A. Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase J. Med. Chem. 2005, 48, 946-961 10.1021/jm049389h
41. Kamal, A.; Shaik, A. A.; Sinha, R.; Yadav, J. S.; Arora, S. K. Antitubercular agents. Part 2: new thiolactomycin analogues active against Mycobacterium tuberculosis Bioorg. Med. Chem. Lett. 2005, 15, 1927-1929 10.1016/j.bmcl.2005.01.084
42. Still, I. W. J.; Drewery, M. J. Synthesis of 2-butenolide and tetronic acid analogs of thiolactomycin J. Org. Chem. 1989, 54, 290-295 10.1021/jo00263a007
43. Kim, P.; Zhang, Y. M.; Shenoy, G.; Nguyen, Q. A.; Boshoff, H. I.; Manjunatha, U. H.; Goodwin, M. B.; Lonsdale, J.; Price, A. C.; Miller, D. J.; Duncan, K.; White, S. W.; Rock, C. O.; Barry, C. E.; Dowd, C. S. Structure-activity relationships at the 5-position of thiolactomycin: An intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli J. Med. Chem. 2006, 49, 159-171 10.1021/jm050825p
44. McFadden, J. M.; Frehywot, G. L.; Townsend, C. A. A flexible route to (5R)-thiolactomycin, a naturally occurring inhibitor of fatty acid synthesis Org. Lett. 2002, 4, 3859-3862 10.1021/ol026685k
45. Chambers, M. S.; Thomas, E. J.; Williams, D. J. An asymmetric-synthesis of thiotetronic acids using chirality transfer via an allyl xanthate-to-dithiocarbonate rearrangement-X-ray crystal-structure of (5r)-2,5-dihydro-4-hydroxy-5-methyl-3-phenyl-5-prop-1′-enyl-2-oxothiophene J. Chem. Soc., Chem. Commun. 1987, 0, 1228-1230 10.1039/C39870001228
46. Chambers, M. S.; Thomas, E. J. Asymmetric synthesis of 5,5-disubstituted thiotetronic acids using an allyl xanthate to dithiocarbonate rearrangement: total synthesis of (5S)-thiolactomycin with revision of the absolute configuration of the natural J. Chem. Soc., Perkin Trans. 1 1997, 417-432 10.1039/a605768c
47. Ohata, K.; Terashima, S. Efficient synthesis of enantiomeric pairs of thiolactomycin and its 3-demethyl derivative Tetrahedron Lett. 2006, 47, 2787-2791 10.1016/j.tetlet.2006.02.058
48. Ohata, K.; Terashima, S. Synthesis and biological activity of enantiomeric pairs of 5-vinylthiolactomycin congeners Bioorg. Med. Chem. Lett. 2007, 17, 4070-4074 10.1016/j.bmcl.2007.04.067
49. Ohata, K.; Terashima, S. Synthesis and biological activity of enantiomeric pairs of 5-[(E)-cycloalk-2-enylidenemethyl]thiolactomycin congeners Bioorg. Med. Chem. Lett. 2008, 18, 5598-5600 10.1016/j.bmcl.2008.08.103
50. Ohata, K.; Terashima, S. Synthesis and biological activity of enantiomeric pairs of 5-(alk-2-enyl)thiolactomycin and 5-[(e)-cycloalk-2-enylidenemethyl]thiolactomycin congeners Chem. Pharm. Bull. 2009, 57, 920-936 10.1248/cpb.57.920
51. Dormann, K. L.; Bruckner, R. Variable synthesis of the optically active thiotetronic acid antibiotics thiolactomycin, thiotetromycin, and 834-B1 Angew. Chem., Int. Ed. 2007, 46, 1160-1163 10.1002/anie.200603562
52. Schiebel, J.; Kapilashrami, K.; Fekete, A.; Bommineni, G. R.; Schaefer, C. M.; Mueller, M. J.; Tonge, P. J.; Kisker, C. Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis J. Biol. Chem. 2013, 288, 34190-34204 10.1074/jbc.M113.511436
53. Luckner, S. R.; Machutta, C. A.; Tonge, P. J.; Kisker, C. Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin Structure 2009, 17, 1004-1013 10.1016/j.str.2009.04.012
54. Hori, K.; Arai, M.; Nomura, K.; Yoshii, E. An efficient 3(C)-acylation of tetramic acids involving acyl migration of 4(O)-acylates Chem. Pharm. Bull. 1987, 35, 4368-4371 10.1248/cpb.35.4368
55. Jeong, Y. C.; Moloney, M. G. Synthesis of and tautomerism in 3-acyltetramic acids J. Org. Chem. 2011, 76, 1342-1354 10.1021/jo102304y
56. am Ende, C. W.; Knudson, S. E.; Liu, N.; Childs, J.; Sullivan, T. J.; Boyne, M.; Xu, H.; Gegina, Y.; Knudson, D. L.; Johnson, F.; Peloquin, C. A.; Slayden, R. A.; Tonge, P. J. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 3029-3033 10.1016/j.bmcl.2008.04.038